We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Assay Used to Diagnose Buruli Ulcer.

By LabMedica International staff writers
Posted on 29 Oct 2012
Print article
A simple diagnostic test for the causative agent of Buruli Ulcer has been reported, which could be used at point of care facilities, in resource-poor settings.

The quick and inexpensive diagnostic test can identify Mycobacterium ulcerans, the bacterium responsible for Buruli Ulcer (BU), and could replace the current laboratory diagnosis based on microscopy, which has to be confirmed by polymerase chain reaction (PCR) and other tests in reference laboratories.

Scientists at the Noguchi Memorial Institute for Medical Research (Accra, Ghana) employed the methodology based on the loop mediated isothermal amplification (LAMP) technique. Four sets of Primers, targeting the mycolactone encoding plasmid genome sequence of M. ulcerans were designed. The BU-LAMP assay was developed and tested on five M. ulcerans strains from patients in Ghana and two reference isolates. The BU-LAMP assay protocol was optimized for maximum efficiency, using the Loopamp DNA amplification kit (Eiken Chemical; Tokyo, Japan).

The assay was tested on other closely related, mycolactone-producing mycobacterial strains; M. marinum, M. liflandii and M. pseudoshotsii, as well as experimentally infected laboratory animal and clinical samples. The results revealed a high specificity of the BU-LAMP assay for selectively detecting M. ulcerans. Compared to the conventional PCR, the new assay is cheaper, simpler, and ten times more sensitive. The test results can be obtained within one hour. The DNA concentration at the visual detection limit was estimated to be 48 pg/μL. However, by measuring the optical density (OD) value of BU-LAMP products at 350 and 450 nm, the scientists were able to detect positivity when using DNA concentrations as low as 0.5 fg/μL.

The authors concluded that the BU-LAMP method shows promise as a diagnostic tool at point of care facilities in BU endemic communities. Unlike the conventional PCR method that requires the use of a thermal cycler, purified DNA samples are not a requirement. DNA amplification occurs within one hour and the resulting product is a turbid solution, indicative of product amplification. Sample confirmation can therefore be done visually with the naked eye, and the intensity of the fluorescence observed is indicative of amount of DNA present. The study was first published online on January 12, 2012, in the journal BMC Infectious Diseases.

Related Links:

Noguchi Memorial Institute for Medical Research
Eiken Chemical


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Gold Member
Troponin T QC
Troponin T Quality Control
New
Automated Biochemistry Analyzer
AutoChem B861
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.